Table 2.
Clinical characteristics of patients.
| Subject | Baseline diagnosis | Style of previous therapy |
Response to previous therapy |
Style of DAC therapy |
Response to DAC therapy | PFS to DAC therapy |
|---|---|---|---|---|---|---|
| UPN 1* | Gastric cardia adenocarcinoma | Chemo × 4, TACE × 2 | PD | DAC | PD | 0 |
| UPN 2 | Colorectal adenocarcinoma | Chemo × 10, surgery | PD | DAC | SD | 3 |
| UPN 3 | Hepatocellular carcinoma | TACE, live transplant | PD | DAC | PD | 5 |
| UPN 4* | Gastric cancer | Chemo × 12 | PD | DAC | PD | 0 |
| UPN 5** | Esophageal adenocarcinoma | Surgery | PD | DAC | SD | 5 |
| UPN 6* | Intrahepatic bile ducts adenocarcinoma | Radiation | PD | DAC | PD | 2 |
| UPN 7* | Alveolar carcinoma | Chemo × 4, radiation | PD | DAC | PD | 1 |
| UPN 8 | Malignant pleural tumors | Chemo × 9 | PD | DAC | PR | 12 |
| UPN 9 | Diffuse large B-cell lymphoma | Chemo × 8 | PD | DAC + chemo | SD | 5 |
| UPN 10* | Non-Hodgkin's lymphoma | Chemo × 5, surgery | PD | DAC + chemo | PD | 0 |
| UPN 11* | Non-Hodgkin's lymphoma | Chemo × 25 | PD | DAC + chemo | PD | 2 |
| UPN 12 | Non-Hodgkin's lymphoma | Chemo × 12 | PD | DAC + chemo | PD | 6 |
| UPN 13* | Non-Hodgkin's lymphoma | Chemo × 9 | PD | DAC + chemo | PD | 2 |
| UPN 14 | Hodgkin's lymphoma | Chemo × 15 | PD | DAC + chemo | SD | 4 |
| UPN 15 | Colon adenocarcinoma | Chemo × 15 | PD | DAC + chemo | PD | 2 |
| UPN 16 | Colorectal cancer | Chemo × 10, gamma knife argon helium knife |
PD | DAC + chemo | SD | 0 |
| UPN 17 | Esophageal squamous cell carcinomas | Chemo × 7, surgery | PD | DAC + chemo | PD | 3 |
| UPN 18 | Cardia adenocarcinoma | Chemo × 5 | PD | DAC + chemo | SD | 6 |
| UPN 19** | Small cell carcinoma of the esophagus | Chemo × 8, surgery, and radiation | PD | DAC + chemo | SD | 2 |
| UPN 20 | Lung adenocarcinoma | Chemo × 3, surgery, and radiation | PD | DAC + chemo |
PR | 4 |
| UPN 21* | Lung adenocarcinoma | Chemo × 4 | PD | DAC + chemo | SD | 5 |
| UPN 22* | Lung adenocarcinoma | Chemo × 7 | PD | DAC + chemo | SD | 4 |
| UPN 23 | Lung adenocarcinoma | Chemo × 6, radiation | PD | DAC + chemo | PD | 3 |
| UPN 24 | Cervical squamous cell carcinomas | Chemo × 10, radiation | PD | DAC + chemo | PD | 4 |
| UPN 25 | Ovary serous papillary cystadenocarcinoma |
Chemo × 28, surgery | PD | DAC + chemo | PR | 5 |
| UPN 26 | Tubal serous adenocarcinoma | Chemo × 10, surgery | PD | DAC + chemo | SD | 7 |
| UPN 27 | Pancreatic cancer | Chemo × 9, surgery | PD | DAC + CIK | SD | 9 |
| UPN 28 | Hepatocellular carcinoma | TACE, radiation | PD | DAC + CIK | SD | 5 |
| UPN 29 | Hepatocellular carcinoma | Surgery, TACE, and radiation | PD | DAC + CIK | PD | 4 |
| UPN 30 | Hepatocellular carcinoma | TACE × 6 | PD | DAC + CIK | SD | 10 |
| UPN 31 | Hepatocellular carcinoma | Surgery, TACE × 2 | PD | DAC + CIK | SD | 8 |
Note. CIK: cytokine induced killer cells; TACE: transcatheter arterial chemoembolization; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK; *patients died because of disease progression or infection; **patient died from giving up treatment for less than three cycles.